Vaccine-Based Prevention of Meningococcal B Disease: Tools for Interpreting and Implementing Recommendations
This activity is supported by an educational grant from GlaxoSmithKline.
Meningococcal disease, specifically serotype B (MenB), is an ongoing problem in this country. The disease can develop from initial symptoms to death within 24 hours. Given how disabling this disease can be it is essential health care workers, who deliver vaccinations, enhance their standards of care in practice in order to deliver the highest rates of preventative care in this area. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MenB vaccination.
Primary care clinicians, pediatricians, Nurses, pharmacists, physician assistants, and all clinicians who treat children/adolescents who are scheduled to receive the MenB vaccine.
Upon completion of the educational activity,participants should be able to:
- Differentiate between types of meningococcal vaccinations with respect to serotypes covered, administration schedule, impact on herd protection and tolerability.
- Interpret Category A and B recommendations in order to better discuss meningococcal B vaccination for patients.
- Utilizing case-based video vignettes, implement strategies to improve uptake of meningococcal B vaccine in clinical practice.
Estimated Time to Complete
Number of Credits
March 9, 2021
March 9, 2022
Provided by Boston University School of Medicine
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This is a knowledge-based educational activity. Pharmacists will receive 1.00 contact hour (0.1 ceus) for the enduring educational activity. No partial credit is available.
Disclosure of Conflicts of Interest Policy
Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Disclosure of Unlabeled Use
The faculty members will discuss the unlabeled/investigational uses of a commercial product.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
FACULTY AND DISCLOSURES
Stephen I. Pelton, MD
Professor of Pediatrics
Boston University School of Medicine
Professor of Epidemiology
Boston University School of Public Health
Director, Section of Pediatric Infectious Diseases
Boston Medical Center
Gary Marshall, MD
Professor of Pediatrics,
Chief, Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Carole Moloney, RN, MSN, CPNP
Clinical Instructor of Pediatrics
Boston University School of Medicine
Gary Marshall, MD receives grant and research support from GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur and Seqirus. He is a speaker for Sanofi Pasteur.
Carole Moloney, NP is on the speaker’s bureau for Sanofi Pasteur.
Stephen Pelton, MD receives Grant/Research/Clinical Trial Support from Pfizer, Merck and Cempra. He is a consultant for Pfizer, GlaxoSmithKline, Sanofi Pasteur and Seqirus.
Dr. Fiorito. Independent Reviewer, has no financial relationships to disclose.
Dr. Pahud is on the advisory board for Sanofi Pasteur, Merck and Pfizer. She has received clinical trial support from GlaxoSmithKline, Astra Zeneca and Pfizer. She is on the speaker's bureau for Sanofi Pasteur and Merck.
Cammie Townsend, DNP, MS/MBA, RN, Accredited Provider Program Director, Elizabeth Drury, Program Manager and Chris Drury, Medical Writer, have no financial relationships to disclose.
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 80% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
For information about the accreditation of this program, please contact firstname.lastname@example.org or www.bucme.org/
© Trustees of Boston University, 2020